Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / BPMC - Blueprint's Avapritinib In Systemic Mastocytosis: A Comparative Analysis

BPMC - Blueprint's Avapritinib In Systemic Mastocytosis: A Comparative Analysis

Blueprint Medicines Corporation
  • BPMC's avapritinib is in post-NDA stage in systemic mastocytosis.
  • Novartis' Rydapt is approved in this indication.
  • However, there are key competitive differences favoring avapritinib.

For further details see:

Blueprint's Avapritinib In Systemic Mastocytosis: A Comparative Analysis
Stock Information
Company Name: Blueprint Medicines Corporation
Stock Symbol: BPMC
Market: NASDAQ
Website: blueprintmedicines.com
Menu
BPMC BPMC Quote BPMC Short BPMC News BPMC Articles BPMC Message Board
Get BPMC Alerts

News, Short Squeeze, Breakout and More Instantly...